anmelden
SLI
2.214,49
PKT
+3,85
PKT
+0,17
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 09.02.23 | Zurich Insurance Hold | Jefferies & Company Inc. | |
| 09.02.23 | UBS Hold | Jefferies & Company Inc. | |
| 09.02.23 | Zurich Insurance Overweight | JP Morgan Chase & Co. | |
| 09.02.23 | UBS Neutral | JP Morgan Chase & Co. | |
| 09.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 08.02.23 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 07.02.23 | UBS Neutral | UBS AG | |
| 07.02.23 | Roche Neutral | UBS AG | |
| 07.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 07.02.23 | Novartis Sell | Deutsche Bank AG | |
| 06.02.23 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 06.02.23 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 06.02.23 | Roche Sell | Deutsche Bank AG | |
| 06.02.23 | UBS Buy | Deutsche Bank AG | |
| 03.02.23 | Roche Outperform | Credit Suisse Group | |
| 03.02.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 03.02.23 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 03.02.23 | Roche Sell | Deutsche Bank AG | |
| 02.02.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 02.02.23 | ABB (Asea Brown Boveri) Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 02.02.23 | Roche Hold | Jefferies & Company Inc. | |
| 02.02.23 | Novartis Underperform | Credit Suisse Group | |
| 02.02.23 | Novartis Sell | Deutsche Bank AG | |
| 02.02.23 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 02.02.23 | ABB (Asea Brown Boveri) Buy | Goldman Sachs Group Inc. | |
| 02.02.23 | ABB (Asea Brown Boveri) Outperform | RBC Capital Markets | |
| 02.02.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 02.02.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 02.02.23 | UBS Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.23 | Novartis Buy | Jefferies & Company Inc. | |
| 01.02.23 | Novartis Neutral | UBS AG | |
| 01.02.23 | UBS Neutral | Credit Suisse Group | |
| 01.02.23 | UBS Outperform | RBC Capital Markets | |
| 01.02.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 01.02.23 | UBS Underweight | Barclays Capital | |
| 01.02.23 | UBS Buy | Deutsche Bank AG | |
| 01.02.23 | UBS Overweight | JP Morgan Chase & Co. | |
| 31.01.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 31.01.23 | Givaudan Sell | UBS AG |
